| The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
|
| Author(s): Paul Cottu 1, Scott David Ramsey 2, Oriol Solà-Morales 3, Patricia A Spears 4, Lockwood Taylor 5 |
| Affiliations(s): 1Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris, France. Electronic address: paul.cottu@curie.fr.
2Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2-B232, Seattle, WA, 98155, USA. Electronic address: sramsey@fredhutch.org.
3Health Innovation Technology Transfer Foundation, Aragó 60, E-08015, Barcelona, Spain. Electronic address: osola@fhitt.org.
48605 Carolingian Court, Raleigh, NC, 27615, USA. Electronic address: paspears88@gmail.com.
5Epidemiology, Real World Solutions at IQVIA, 4820 Emperor Boulevard, Durham, NC, 27703, USA. Electronic address: lockwood.taylor@iqvia.com. |
Publication(s): Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015.
|
| Document Type(s): Article, |
| Countries: France, Italy, USA, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Drug safety, Oncology, Regulatory,
2022 |
|
L:
A: |
English
Review, |
|
 |
| |
| |
| POSB392 Understanding the Secondary Care Characteristics and Pathways of Multiple Myeloma Patients Who Reach Second-Line Therapy Using the Hospital Episode Statistics (HES) Database
|
| Author(s): E Mary Babu
S Fermahan
S Chavda
M Chetty
S Navani
A Matthew
R Hudson |
| Affiliations(s): Sanofi, Reading, RDG, UK
IQVIA, London, UK |
Publication(s): Mary Babu, E et al.
Value in Health, Volume 25, Issue 1, S257
|
| Document Type(s): Abstract, Article, |
| Countries: England, |
| Click here for the abstract |
C:
Y: |
Oncology,
2022 |
|
L:
A: |
English
Burden of illness, clinical setting: Secondary care, Database Study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan |
| Author(s): Masaki Shiota 1, Raf De Moor 2, Yosuke Koroki 2, Dae Young Yu 3, David Bin-Chia Wu 4 (rwesheorj A) |
| Affiliations(s): 1) Department of Urology, Graduate School of Medical Sciences, Kyushu University Hospital, Fukuoka, Japan
2) Integrated Market Access, Janssen Pharmaceutical KK, Tokyo, Japan
3) Janssen Pharmaceutical Companies of Johnson and Johnson, Asia Pacific Regional Office, Singapore, Singapore
4) Janssen Pharmaceutical Companies of Johnson and Johnson, Asia Pacific Regional Office, Singapore, Singapore;e Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore;f School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia |
Publication(s): Current Medical Research and Opinion
|
| Document Type(s): Article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Oncology,
2022 |
|
L:
A: |
English
Database Study, |
|
|
| |
| |
| Validation of safety outcomes in routinely collected data: lessons learned from a multinational post-approval safety study
|
| Author(s): Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V.
|
| Affiliations(s): "Pfizer Inc., New York, New York, United States of America.
Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, United States of America.
EPID Research (an IQVIA company), Espoo, Finland."
|
Publication(s): Pharmacoepidemiol Drug Saf. 2022 Dec 10. doi: 10.1002/pds.5582
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Netherlands , Sweden, USA, |
| Click here for the abstract |
C:
Y: |
Database Validity and methodology, Drug safety, Oncology,
2022 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Retrospective database analysis, |
|
|
| |
| |
| Patients' preferences for attributes of molecular targeting therapies for advanced non-small cell lung cancer with EGFR mutations in Japan - a discrete-choice experiment |
| Author(s): Kazuhiko Nakagawa 1, Yoshinori Tanizawa 2, Zhihong Cai 2, Tomoko Matsui 2, Sotaro Enatsu 2 (rwesheorj A) |
| Affiliations(s): 1) Kindai University, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
2) Eli Lilly Japan K.K., Japan Drug Development and Medical Affairs, Kobe, Japan |
Publication(s): Japanese Journal of Cancer and Chemotherapy
|
| Document Type(s): Article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Oncology,
2022 |
|
L:
A: |
Japanese
Patient questionnaire, |
|
|
| |
| |
| Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer |
| Author(s): Hiroyuki Matsuda 1, Toru Ogawa 2*, Yasunari Sadatsuki 3, Toshiaki Tsujino 3, Shingo Wada 1, Seok-Won Kim 1, Yutaka Hatanaka 4 (rwesheorj 1) |
| Affiliations(s): 1) Real World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., Tokyo, Japan
2) Market Access Oncology, Bayer Yakuhin, Ltd, Osaka, Japan
3) Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan
4) Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Hokkaido, Japan |
Publication(s): Respiratory Investigation
|
| Document Type(s): Article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Oncology,
2022 |
|
L:
A: |
English
Budget impact, Database Study, |
|
|
| |
| |
| Characteristics, treatment patterns, and healthcare costs of advanced/metastatic biliary tract cancer patients in Japan |
| Author(s): CC Chen 1, X Wang 1, Seok-Won Kim 2*, Shingo Wada 2, J Garside 3, ES Reese 4 (rwesheorj 2) |
| Affiliations(s): 1) IQVIA, Plymouth Meeting, PA, USA
2) IQVIA, Tokyo, Japan
3) GlaxoSmithKline, London, UK
4) EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA |
Publication(s): Japanese Society of Medical Oncology Annual Meeting
|
| Document Type(s): Conference, Oral presentation, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Oncology,
2022 |
|
L:
A: |
English
Database Study, |
|
|
| |
| |
| Prognosis of lung cancer patients treated with immune checkpoint inhibitors with or without antimicrobial history |
| Author(s): Ryohei Kobayashi 1, Kenji Kanagawa 1, Sanesue Yasukawa 1, Takuma Kondo 1, Shingo Wada 2 (rwesheorj 2) |
| Affiliations(s): 1) IQVIA Services Japan K.K.
2) IQVIA Solutions Japan K.K. |
Publication(s): The 27th Annual Meeting of the Japanese Society for Pharmacoepidemiology
|
| Document Type(s): Conference, Oral presentation, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Oncology,
2022 |
|
L:
A: |
Japanese
Database Study, Retrospective cohort analysis, |
|
|
| |
| |
| High?Expenditure Disease in the EU?28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? |
| Author(s): Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck |
| Affiliations(s): Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium |
Publication(s): PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4
|
| Document Type(s): Article, |
| Countries: Europe, |
| Click here for the abstract |
C:
Y: |
Diabetes, Health economics, Oncology,
2021 |
|
L:
A: |
English
Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review, |
|
|
| |
| |
| Analisi di impatto sul budget sanitario italiano di gilteritinib per il trattamento della leucemia mieloide acuta FLT3+ recidivante o refrattaria
|
| Author(s): Fiorentino F, La Malfa P, Di Rienzo P
|
| Affiliations(s): Fiorentino F: IQVIA Solutions Italy Srl, RWS
|
Publication(s): GIHTAD (2021) 14:4
|
| Document Type(s): Article, |
| Countries: Italy, |
| Click here for the abstract |
C:
Y: |
Health economics, Oncology,
2021 |
|
L:
A: |
Italian
Budget impact, clinical setting: Secondary care, |
|
|
| |
| |
 1 of 60 
|
